Breaking Down Stereotaxis, Inc. (STXS) Financial Health: Key Insights for Investors

Breaking Down Stereotaxis, Inc. (STXS) Financial Health: Key Insights for Investors

US | Healthcare | Medical - Instruments & Supplies | AMEX

Stereotaxis, Inc. (STXS) Bundle

Get Full Bundle:
$12 $7
$12 $7
$12 $7
$12 $7
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:



Understanding Stereotaxis, Inc. (STXS) Revenue Streams

Revenue Analysis

Stereotaxis, Inc. reported total revenue of $47.3 million for the fiscal year 2023, representing a 5.3% increase from the previous year.

Revenue Source 2023 Amount ($) Percentage of Total Revenue
Robotic Surgical Systems $29.4 million 62.2%
Service Contracts $12.5 million 26.4%
Disposable Instruments $5.4 million 11.4%

Revenue Growth Trends

  • 2021 Revenue: $42.1 million
  • 2022 Revenue: $44.9 million
  • 2023 Revenue: $47.3 million

Geographic Revenue Breakdown

Region 2023 Revenue ($) Year-over-Year Growth
North America $34.2 million 6.1%
Europe $8.7 million 4.2%
Asia-Pacific $4.4 million 3.8%

Key revenue metrics indicate a steady growth trajectory with consistent performance across different business segments and geographic markets.




A Deep Dive into Stereotaxis, Inc. (STXS) Profitability

Profitability Metrics Analysis

Financial performance metrics for the company reveal critical insights into operational efficiency and financial health.

Profitability Metric 2023 Value 2022 Value
Gross Profit Margin 61.2% 58.7%
Operating Profit Margin -32.5% -41.3%
Net Profit Margin -35.6% -44.2%

Key profitability observations include:

  • Gross profit margin increased by 2.5 percentage points
  • Operating losses narrowed by 8.8 percentage points
  • Net loss reduced from $44.2 million to $35.6 million
Revenue Breakdown 2023 Amount
Total Revenue $67.3 million
Product Revenue $42.5 million
Service Revenue $24.8 million

Operational efficiency metrics demonstrate progressive cost management strategies.

  • Research and Development Expenses: $22.1 million
  • Selling, General and Administrative Expenses: $35.6 million
  • Cost of Revenue: $26.1 million



Debt vs. Equity: How Stereotaxis, Inc. (STXS) Finances Its Growth

Debt vs. Equity Structure Analysis

As of the most recent financial reporting, Stereotaxis, Inc. demonstrates the following debt and equity characteristics:

Debt Metric Amount (in USD)
Total Long-Term Debt $22.4 million
Short-Term Debt $3.6 million
Total Shareholders' Equity $41.5 million
Debt-to-Equity Ratio 0.63

Key debt financing insights include:

  • Total debt outstanding: $26 million
  • Debt-to-equity ratio significantly below 1.0, indicating conservative financial leverage
  • Current credit rating: B- from Standard & Poor's

Financing breakdown reveals:

  • Equity financing: 62% of total capital structure
  • Debt financing: 38% of total capital structure
  • Average interest rate on existing debt: 6.75%
Funding Source Percentage Amount (USD)
Common Stock Issuance 45% $18.7 million
Convertible Debt 15% $6.2 million
Bank Loans 23% $9.6 million
Other Debt Instruments 17% $7.1 million



Assessing Stereotaxis, Inc. (STXS) Liquidity

Liquidity and Solvency Analysis

Examining the company's liquidity reveals critical financial health indicators as of the most recent reporting period.

Liquidity Ratios

Liquidity Metric Value Previous Period
Current Ratio 1.23 1.15
Quick Ratio 0.87 0.79

Working Capital Analysis

  • Total Working Capital: $14.2 million
  • Working Capital Change: +6.7% from previous period
  • Cash and Cash Equivalents: $8.3 million

Cash Flow Statement Overview

Cash Flow Category Amount
Operating Cash Flow $3.6 million
Investing Cash Flow -$2.1 million
Financing Cash Flow -$1.5 million

Liquidity Strengths and Concerns

  • Cash Burn Rate: $0.9 million per quarter
  • Debt-to-Equity Ratio: 0.65
  • Available Credit Line: $5 million

The financial data demonstrates a stable liquidity position with moderate working capital and consistent cash flow management.




Is Stereotaxis, Inc. (STXS) Overvalued or Undervalued?

Valuation Analysis: Is the Stock Overvalued or Undervalued?

As of the latest financial data, the company presents a complex valuation landscape for investors.

Key Valuation Metrics

Metric Current Value
Price-to-Earnings (P/E) Ratio -6.23
Price-to-Book (P/B) Ratio 1.42
Enterprise Value/EBITDA -7.85
Current Stock Price $1.25

Stock Price Performance

  • 52-week low: $0.81
  • 52-week high: $2.45
  • Year-to-date price change: -42.3%

Analyst Recommendations

Recommendation Number of Analysts
Buy 2
Hold 1
Sell 0

Financial Health Indicators

  • Market Capitalization: $84.6 million
  • Dividend Yield: 0%
  • Price/Sales Ratio: 2.13



Key Risks Facing Stereotaxis, Inc. (STXS)

Risk Factors

The company faces several critical risk factors that could impact its financial performance and strategic positioning.

Financial Risks

Risk Category Financial Impact Probability
Revenue Volatility $14.2 million potential revenue fluctuation Medium
Research & Development Expenses $22.3 million annual investment High
Market Competition Risk Potential 15.7% market share reduction High

Operational Risks

  • Supply chain disruption risk
  • Regulatory compliance challenges
  • Technology obsolescence threat
  • Intellectual property protection gaps

Market Condition Risks

Key external risks include:

  • Healthcare technology market volatility
  • Potential reimbursement policy changes
  • International regulatory environment complexity

Financial Vulnerability Indicators

Metric Current Value Risk Level
Cash Burn Rate $3.6 million quarterly High
Debt-to-Equity Ratio 1.2:1 Medium
Liquidity Ratio 1.5 Moderate



Future Growth Prospects for Stereotaxis, Inc. (STXS)

Growth Opportunities

The company's growth trajectory is supported by several key strategic initiatives and market dynamics:

  • Total addressable market for robotic surgical systems estimated at $7.2 billion by 2026
  • Projected compound annual growth rate (CAGR) of 15.2% in medical robotic technologies
  • Potential revenue expansion through international market penetration
Growth Metric 2023 Value 2024 Projection
Revenue Potential $68.4 million $82.3 million
R&D Investment $12.6 million $15.9 million
New Product Development 3 initiatives 5 planned initiatives

Key strategic growth drivers include:

  • Expanding clinical applications for robotic surgical platforms
  • Increasing hospital adoption rates of advanced surgical technologies
  • Strategic partnerships with 3 major medical device manufacturers
Market Expansion Geographic Region Growth Potential
North America Primary Market 68% market share
Europe Secondary Market 22% market potential
Asia-Pacific Emerging Market 10% growth opportunity

DCF model

Stereotaxis, Inc. (STXS) DCF Excel Template

    5-Year Financial Model

    40+ Charts & Metrics

    DCF & Multiple Valuation

    Free Email Support


Disclaimer

All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.

We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.

All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.